Peer Review reports
From: Access to essential and innovative anti-cancer medicines: a longitudinal study in Nanjing, China
| Original Submission | ||
|---|---|---|
| 18 Oct 2023 | Submitted | Original manuscript |
| 2 Nov 2023 | Author responded | Author comments - Xin Li |
| Resubmission - Version 2 | ||
| 2 Nov 2023 | Submitted | Manuscript version 2 |
| 24 Dec 2023 | Reviewed | Reviewer Report - Shinya Suzuki |
| 12 Jan 2024 | Reviewed | Reviewer Report |
| 23 Feb 2024 | Reviewed | Reviewer Report |
| 14 Mar 2024 | Author responded | Author comments - Xin Li |
| Resubmission - Version 3 | ||
| 14 Mar 2024 | Submitted | Manuscript version 3 |
| 14 May 2024 | Author responded | Author comments - Xin Li |
| Resubmission - Version 4 | ||
| 14 May 2024 | Submitted | Manuscript version 4 |
| Publishing | ||
| 8 Jul 2024 | Editorially accepted | |
| 11 Jul 2024 | Article published | 10.1186/s12913-024-11285-5 |
You can find further information about peer review here.